Home/Filings/4/0001493152-22-015773
4//SEC Filing

Huntsman Ronald Kirk 4

Accession 0001493152-22-015773

CIK 0001716166other

Filed

Jun 2, 8:00 PM ET

Accepted

Jun 3, 6:08 AM ET

Size

7.5 KB

Accession

0001493152-22-015773

Insider Transaction Report

Form 4
Period: 2022-05-31
Huntsman Ronald Kirk
DirectorChief Executive Officer10% Owner
Transactions
  • Purchase

    Common Stock

    2022-06-01$1.83/sh+4,000$7,32027,500 total
  • Purchase

    Common Stock

    2022-05-31$2.03/sh+8,000$16,24023,500 total
Holdings
  • Common Stock

    (indirect: See footnote)
    1,740,000
Footnotes (2)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in four separate transactions ranging from $2.02 to $2.035 on May 31, 2022. The reporting person undertakes to provide to Vivos Therapeutics, Inc., any security holder of Vivos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
  • [F2]Shares held by Coronado V Partners, LLC, of which the reporting person is a member and manager.

Documents

1 file

Issuer

Vivos Therapeutics, Inc.

CIK 0001716166

Entity typeother

Related Parties

1
  • filerCIK 0001835498

Filing Metadata

Form type
4
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 6:08 AM ET
Size
7.5 KB